J. Kevin Buchi, Director at STEMLINE THERAPEUTICS INC (STML), bought 500 shares at $10.00 ($5K) on 2013-01-29, disclosed to the SEC on 2013-01-30.
Open-market purchase of $5k STML by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| AMPE | BUY | 2023-05-17 | $9K | — | Filing → |
| AMPE | BUY | 2023-05-16 | $17K | — | Filing → |
| TLOG | BUY | 2015-03-30 | $21K | — | Filing → |